Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             111 results found
no title author magazine year volume issue page(s) type
1 Absence of the X1st gene from the late replicating isodicentric X chromosome in myelodysplasia Oscier, D.
 1994
 18 S p. 45-
1 p.
 article
2 Acute myeloblastic leukemia (AML) with trilineage myelodysplasia (TMD+): characteristics and prognosis Rajić, Nebojša
 1994
 18 S p. 37-
1 p.
 article
3 Affection of CD 34-positive progenitor cells by chromosome abnormalities and karyotype evolution in a case of secondary MDS Haase, Detlef
 1994
 18 S p. 44-
1 p.
 article
4 Allogeneic bone marrow transplantation for MDS: One institution's experience with one regimen Ratanatharathorn, Voravit
 1994
 18 S p. 66-
1 p.
 article
5 Allogeneic bone marrow transplantation in childhood chronic myelomonocytic leukemia. A report on behalf of the European Working group on childhood myelodysplastic syndromes (EWOG-MDS) van 't Veer-Korthof, E.T.
 1994
 18 S p. 25-
1 p.
 article
6 Allogeneic marrow transplantation for myelodysplastic syndrome (MDS) using unrelated donors (URD) Anderson, J.E.
 1994
 18 S p. 26-
1 p.
 article
7 Allogenic bone marrow transplantation (BMT) in RAEB/RAEBt patients-optimal time (model II) Popović, Stevan
 1994
 18 S p. 66-
1 p.
 article
8 An association between telomere shortening and disease evolution patterns in MDS Ohyashiki, Kazuma
 1994
 18 S p. 9-
1 p.
 article
9 ANLL following autologous bone marrow transplantation Roman-Unfer, Susan
 1994
 18 S p. 46-
1 p.
 article
10 A phase III trial of subcutaneous administration of rhG-CSF in the myelodysplastic syndromes Yoshida, Y.
 1994
 18 S p. 17-
1 p.
 article
11 A randomized trial of hydroxyuea (HY) versus VP16 in advanced adult chronic myelomonocytic leukemia Wattel, E.
 1994
 18 S p. 21-
1 p.
 article
12 A randomized trial of two doses of IL-3 in patients with MDS Stone, R.M.
 1994
 18 S p. 18-
1 p.
 article
13 Atypical chronic myeloid leukeamia. Is it a separate entity? Oscier, D.G.
 1994
 18 S p. 37-
1 p.
 article
14 A unique karyotype with low level mosaicism: 45, X, -Y, del(20q)/46, XY, del(20q) in a myelodysplastic syndrome surfaces using FISH technology David, K.
 1994
 18 S p. 43-
1 p.
 article
15 Author index 1994
 18 S p. I-III
nvt p.
 article
16 Autoimmune phenomena in myelodysplastic syndromes: Response to immunosuppressive therapy Enright, Helen
 1994
 18 S p. 54-
1 p.
 article
17 5-Azacytidine in myelodysplastic syndromes (MDS): The experience at mount Sinai Hospital, New York Silverman, Lewis R.
 1994
 18 S p. 21-
1 p.
 article
18 Bone marrow transplantation for myelodysplastic syndromes and secondary acute myelocytic leukemia Castro-Malaspina, H.
 1994
 18 S p. 65-
1 p.
 article
19 Cell biology and programmed cell death in MDS Yoshida, Yataro
 1994
 18 S p. 5-
1 p.
 article
20 Characteristics of the hemopoietic abnormalities after chronic exposure to benzene Ruiz, M.A.
 1994
 18 S p. 29-
1 p.
 article
21 Childhood MDS treated with AML regimens Hasle, Henrik
 1994
 18 S p. 25-
1 p.
 article
22 Chromosomal abnormalities in myelodisplastic syndromes (MDS) in the Mexican population Arana Trejo, Rosa Ma.
 1994
 18 S p. 45-
1 p.
 article
23 Chronic myelomonocytic leukemia (CMML) in childhood Niemeyer, C.
 1994
 18 S p. 6-
1 p.
 article
24 Clinical and laboratory analysis of patients with deletions of part of chromosome 5q Wos, E.
 1994
 18 S p. 43-
1 p.
 article
25 Clinical trials of G-CSF and erythropoietin (Epo) in MDS Greenberg, Peter L.
 1994
 18 S p. 21-
1 p.
 article
26 Cloning and characterization of the t(5; 12) translocation breakpoint associated with chronic myelomonocytic leukemia (CMML) Golub, Todd
 1994
 18 S p. 13-
1 p.
 article
27 Comparative risk factor analysis in Japanese patients with myelodysplastic syndromes Ohyashiki, Kazuma
 1994
 18 S p. 40-
1 p.
 article
28 Comparative study of the prognostic value for survival and leukemic transformation of three different scoring systems in MDS: Experience of the Spanish cooperative group on MDS Sanz, G.F.
 1994
 18 S p. 38-
1 p.
 article
29 Comparison between the FAB system and three prognostic scoring systems in 245 untreated patients with de novo MDS. The lille experience Morel, P.
 1994
 18 S p. 38-
1 p.
 article
30 Comparison of different scoring systems for risk analysis in MDS Aul, C.
 1994
 18 S p. 39-
1 p.
 article
31 Comparison of four categorized risk scoring systems for analyzing outcome in advanced MDS Greenberg, P.
 1994
 18 S p. 40-
1 p.
 article
32 Comparison of four prognostic scores for survival and transformation in MDS Mufti, Ghulam J.
 1994
 18 S p. 6-
1 p.
 article
33 Comparison of scoring systems for prognosis in MDS Kruger, A.
 1994
 18 S p. 40-
1 p.
 article
34 Concordance/discordance in assessing leukemic evolution between three different scoring systems in MDS: The experience of the Spanish cooperative group on MDS Lopez, F.
 1994
 18 S p. 38-
1 p.
 article
35 Concordance/discordance in assessing survival between three different scoring systems in MDS: The experience of the Spanish cooperative group on MDS Sanz, G.F.
 1994
 18 S p. 38-
1 p.
 article
36 Cytogenetic analysis in fifty patients with myelodysplastic syndrome Fernandez, Teresa S.
 1994
 18 S p. 44-
1 p.
 article
37 Cytokine level in the serum of AML and MDS patients Depaoli, Lorella
 1994
 18 S p. 53-
1 p.
 article
38 Cytomorphological results and dysplastic features as prognostic factors in 41 cases with acute myeloid leukemia (AML) and translocation Haferlach, T.
 1994
 18 S p. 45-
1 p.
 article
39 Differential diagnosis of myelodysplasia (MDS) and erythroleukemia (FAB:M6): A multicenter I.G.C.I. trial Krieger, O.
 1994
 18 S p. 36-
1 p.
 article
40 Dysmegakaryopoiesis versus amegakaryopiesis in patients with primary MDS Yavorkovsky, Leonid L.
 1994
 18 S p. 33-
1 p.
 article
41 Dysplastic hematopoiesis following orthotopic liver transplantation: Comparison with similar changes in HIV-infection and primary myelodysplasia Clatch, Richard J.
 1994
 18 S p. 30-
1 p.
 article
42 Effective erythroid output and reticulocyte to red cell maturation in MDS patients measured using the Technicon H3 analyser Bowen, David T.
 1994
 18 S p. 34-
1 p.
 article
43 Epidemiology of MDS in childhood Hasle, Henrik
 1994
 18 S p. 1-
1 p.
 article
44 Erythropoietin-independent erythroid progenitors in patients with sideroblastic anaemia and thrombocytosis Oscler, D.G.
 1994
 18 S p. 37-
1 p.
 article
45 Erythropoietin levels and the medullary hematopoietic pool of myelodysplastic syndrome Kageyama, Takashi
 1994
 18 S p. 37-
1 p.
 article
46 Evaluation of the distributions of cellular marrow by using magnetic resonance imaging(MRI) in patients with myelodysplastic syndromes and aplastic anemia Tsushima, Hideki
 1994
 18 S p. 34-
1 p.
 article
47 Exposure to occupational and environmental factors in MDS. Preliminary results of a case control study Nisse, C.
 1994
 18 S p. 1-
1 p.
 article
48 Expression of the EVI-1 gene in myelodysplastic syndromes Dreyfus, F.
 1994
 18 S p. 50-
1 p.
 article
49 Extremely high incidence of apoptosis may explain ineffective hematopoiesis in myelodysplastic syndromes (MDS) Raza, A.
 1994
 18 S p. 13-
1 p.
 article
50 Fish and “Fiction” analysis of chromosome 7 in MDS : a study on 99 cases Soenen, V.
 1994
 18 S p. 43-
1 p.
 article
51 Frequency and prognostic value of dysmyelopoiesis in 114 patients with de novo acute myeloid leukemia (AML) in an ongoing study Haferlach, T.
 1994
 18 S p. 36-
1 p.
 article
52 Genetic lesions and clinical outcome in myelodysplasia (MDS) Oscier, David
 1994
 18 S p. 50-
1 p.
 article
53 Growth factor (GF) augmentation of intensive chemotherapy for MDS and AML following MDS Gore, Steven D.
 1994
 18 S p. 25-
1 p.
 article
54 High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) or RAEB in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy Estey, Elihu H.
 1994
 18 S p. 21-
1 p.
 article
55 Histological findings in fifty patients with primary myelodysplastic syndromes Souza, J.M.
 1994
 18 S p. 36-
1 p.
 article
56 Hypocellular AML: A clinical entity with hematological features distinct from MDS Nagai, Kazuhiro
 1994
 18 S p. 35-
1 p.
 article
57 Immunophenotype and genotype of MDS in acute transformation Chen, Y.C.
 1994
 18 S p. 35-
1 p.
 article
58 Impact on survival and leukemic transformation of in vitro growth pattern of granulocyte-macrophage progenitors (CFU-GM) in MDS Garcia, M.
 1994
 18 S p. 54-
1 p.
 article
59 Increased expression of bcl-2 protein in the bone marrow biopsies of patients with primary MDS Lambertenghi Deliliers, G.
 1994
 18 S p. 50-
1 p.
 article
60 Intensive chemotherapy with or without G-CSF in high risk myelodysplastic syndromes (MDS) or acute leukemia (AL) evolving from MDS: Randomized clinical study Bernasconi, C.
 1994
 18 S p. 65-
1 p.
 article
61 In vitro effects of IL-2 and LAK cells on clonogenic potential, blast cell proliferation and cytokine release of MDS bone marrow cells Cortelezzi, A.
 1994
 18 S p. 18-
1 p.
 article
62 Karyotype at diagnosis, subsequent leukemic transformation and survival in MDS Musilová, J.
 1994
 18 S p. 44-
1 p.
 article
63 Lack of c-kit point mutations in patients with myelodysplastic syndromes and other hematopoietic disorders deCastro, Carlos M.
 1994
 18 S p. 49-
1 p.
 article
64 MDS and AML with 17p deletion are associated to specific dysgranulopoiesis and a high incidence of p53 mutations Preudhomme, C.
 1994
 18 S p. 9-
1 p.
 article
65 Microdeletion at the acetylcholinesterase locus at 7q22 associated with myelodysplasia and acute myeloid leukaemia Stephenson, J.
 1994
 18 S p. 13-
1 p.
 article
66 Mixed myelodysplastic and myeloproliferative syndromes Neuwirtová, R.
 1994
 18 S p. 36-
1 p.
 article
67 Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes Asimakopoulos, Fotios A.
 1994
 18 S p. 43-
1 p.
 article
68 Multi-dimensional flow cytometric antigenic comparison of bone marrow from normal, AML and MDS patients Wells, Denise A.
 1994
 18 S p. 5-
1 p.
 article
69 Multiparameter flow cytometry in RAEB patients treated with GM-CSF and low-dose ARA-c Hokland, Peter
 1994
 18 S p. 17-
1 p.
 article
70 Myelodysplasia and its discontents: A patient's perspective Fleischman, Suzanne
 1994
 18 S p. 57-
1 p.
 article
71 Myelodysplastic syndrome in young adults aged 15–35 years. A report on 57 cases Cermak, Jaroslav
 1994
 18 S p. 34-
1 p.
 article
72 Myelodysplastic syndrome (MDS) and cranial nerve paralysis after perchlorethylene (PER) exposure Keiser, Georg
 1994
 18 S p. 29-
1 p.
 article
73 Myelodysplastic syndromes(MDS): Analysis of prognostic factors and scoring systems Souto, E.X.
 1994
 18 S p. 35-
1 p.
 article
74 Myelomonocytic antigen abnormalities on neutrophils and monocytes in myelodysplastic syndromes Bernier, M.
 1994
 18 S p. 5-
1 p.
 article
75 Occupational exposure and cytogenetics in MDS/AML Wong, K.F.
 1994
 18 S p. 1-
1 p.
 article
76 P. glycoprotein (PGP) expression and response to intensive chemotherapy and low dose AraC in myelodysplastic syndromes (MDS). A report on 66 cases Wattel, E.
 1994
 18 S p. 65-
1 p.
 article
77 Phase III multicenter randomized trial in RAEB patients of more than 60 years of age: Ara-C 3mg/m2 versus symptomatic treatment Chomienne, C.
 1994
 18 S p. 22-
1 p.
 article
78 P53 mutations are a strong prognostic factor of response to chemotherapy and survival in myelodysplastic syndromes (MDS) Wattel, E.
 1994
 18 S p. 49-
1 p.
 article
79 Prediction of 18 months survival in patients with primary myelodysplastic syndrome: a regression model and scoring system based on the combination of chromosome findings and the bournemouth score Parlier, V.
 1994
 18 S p. 39-
1 p.
 article
80 Prediction of response to G-CSF and epo treatment for the anaemia of myelodysplastic syndromes (MDS) Hellström-Lindberg, Eva
 1994
 18 S p. 53-
1 p.
 article
81 Pre-leukemic disorders in childhood Lopes, L.F.
 1994
 18 S p. 33-
1 p.
 article
82 Procainamide-associated blood dyscrasias: A 10-year retrospective report Uprichard, Andrew C.G.
 1994
 18 S p. 29-
1 p.
 article
83 Prognosis scoring system in refractory anemia with excess of blast (RAEB) Chevret, S.
 1994
 18 S p. 6-
1 p.
 article
84 Prognostic factors in myelodysplastic syndromes: a cytologic, histologic and cytogenetic study Souza, J.M.
 1994
 18 S p. 35-
1 p.
 article
85 Prognostic importance of type II blasts in refractory anemia with excess of blasts (RAEB). A report on 91 cases Guerci, A.P.
 1994
 18 S p. 39-
1 p.
 article
86 Prognostic value of c- MPL expression in myelodysplastic syndromes Bouscary, D.
 1994
 18 S p. 50-
1 p.
 article
87 Prognostic value of histological parameters and CD34 reactivity in the bone marrow biopsies of MDS patients Lambertenghi Deliliers, G.
 1994
 18 S p. 39-
1 p.
 article
88 Recombinant human erythropoietin (Rhu-Epo) therapy in low grade myelodysplastic syndromes: Role of cytokines Di Stefano, M.
 1994
 18 S p. 18-
1 p.
 article
89 Refractory cytopenia and marrow eosinophilia with intranuclear charcot leyden crystals Wong, K.F.
 1994
 18 S p. 33-
1 p.
 article
90 Relationship between hematological characteristics and granulocyte-macrophage colony formation (CFU-GM) in MDS Garcia, M.
 1994
 18 S p. 53-
1 p.
 article
91 Secondary acute myeloid leukemia as a result of chemotherapy for soft tissue sarcoma Varterasian, Mary
 1994
 18 S p. 29-
1 p.
 article
92 Secondary myelodysplastic syndrome following myeloma therapy Irněný, M.
 1994
 18 S p. 30-
1 p.
 article
93 Serumconcentrations of interleukin-6 soluble receptor (IL-6sR) in patients with MDS Herold, M.
 1994
 18 S p. 18-
1 p.
 article
94 Should auer rods be used in the classification of myelodysplastic syndromes (MDS)? Seymour, J.F.
 1994
 18 S p. 5-
1 p.
 article
95 Spontaneous cytokine production in aplastic anemia and refractiory anemia Koike, M.
 1994
 18 S p. 53-
1 p.
 article
96 Study of clonality and evolution of myelodysplastic syndromes using fluorescence in situ hybridization Abruzzese, E.
 1994
 18 S p. 44-
1 p.
 article
97 Synergistic effect of G-CSF and epo on the anaemia in patients with MDS. Evidence for increased erythropoietic effectiveness rather than expansion Hellström-Lindberg, E.
 1994
 18 S p. 17-
1 p.
 article
98 The erythropoietin receptor gene in myelodysplastic syndromes and other stem cell disorders: A different gene in an MDS patient Mittelman, Moshe
 1994
 18 S p. 49-
1 p.
 article
99 The impact of different cytogenetic subgroups on survival of 203 patients with MDS Vallespi, T.
 1994
 18 S p. 46-
1 p.
 article
100 The management of chronic myelomonocytic leukaemia Oscier, D.G.
 1994
 18 S p. 25-
1 p.
 article
101 The MIP-1-α/RANTES receptor gene in the myelodysplastic syndromes Berger, Mark S.
 1994
 18 S p. 49-
1 p.
 article
102 The 5q-syndrome: Clinical course of 12 patients Lesseve, J.F.
 1994
 18 S p. 45-
1 p.
 article
103 Therapeutic trial of combination of rGM-CSF, androgen therapy and low dose cytosine arabinoside (Ara-C) in RAEB and RAEB-t Guerci, A.P.
 1994
 18 S p. 61-
1 p.
 article
104 Treatment of acute leukemia arising from myelodysplastic syndromes with oral idarubicin, etoposide, and 6-thioguanine Montillo, M.
 1994
 18 S p. 61-
1 p.
 article
105 Treatment of advanced primary myelodysplastic syndromes with AML-type chemotherapy: Results in 76 patients Aul, C.
 1994
 18 S p. 22-
1 p.
 article
106 Treatment of “high risk” myelodysplastic syndromes (MDS) with idarubicin and cytosine arabinoside, supported by granulocyte-macrophage colony stimulating factor (GM-CSF) Economopoulos, T.
 1994
 18 S p. 65-
1 p.
 article
107 Treatment with alpha-lymphoblastoid interferon (wellferon) in high risk myelodysplastic syndromes (HR-MDS) Petti, M.C.
 1994
 18 S p. 61-
1 p.
 article
108 Trilineage dysplasia in de novo AML: Relation to MDS Tomonaga, Masao
 1994
 18 S p. 34-
1 p.
 article
109 Type IV myeloblasts or hypogranular promyelocytes? Wong, K.F.
 1994
 18 S p. 33-
1 p.
 article
110 Update on juvenile CML: Pathogenesis and treatment Emanuel, Peter D.
 1994
 18 S p. 22-
1 p.
 article
111 Very low dose GM-CSF (0.5 or 0.25 μg/kg/d) in MDS. A report on 35 cases Rose, C.
 1994
 18 S p. 17-
1 p.
 article
                             111 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands